Roundtable: How is Myelofibrosis Staged: with Dr. John Mascarenhas, Dr. Raajit Rampal and Dr. Lucia Masarova image

Roundtable: How is Myelofibrosis Staged: with Dr. John Mascarenhas, Dr. Raajit Rampal and Dr. Lucia Masarova

Apr 04, 2025
02:30PM - 04:00PM EDT
Online Event
Overview

Join us for our first HealthTree for Myelofibrosis Roundtable to hear from three of the leading myelofibrosis experts about how myelofibrosis is staged and what those stages mean for you as a patient.

Agenda
2:30 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and our featured speakers Dr. John Mascarenhas, Dr. Raajit Rampal and Dr. Lucia Masarova

2:35 PM
What is Myelofibrosis and How Is It Staged?
Lucia Masarova, MD

Dr. Lucia Masarova shares an overview of myelofibrosis and how it's staged 

2:55 PM
What is "Low-Risk" Myelofibrosis and Treatment Options
Raajit Ramal, MD, PhD

Dr. Rampal discusses "low-risk" myelofibrosis and what treatment looks like for this group of patients. 

3:15 PM
What is "High-Risk" Myelfibrosis and Treatment Options
John Mascarenhas, MD

Dr. Mascarenhas discusses high-risk myelofibrosis and treatment options for this group

3:35 PM
Questions and Answers
Audience

Type your questions in the chat for our experts to answer! 

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the CLL Education Manager.

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Lucia Masarova, MD

Lucia Masarova, MD

Dr. Lucia Masarova is an Assistant Professor at the Leukemia Department at the MD Anderson Cancer Center. Her clinical and research focus is on myeloproliferative neoplasms, and she is particularly interested in developing novel therapies to address the complex needs of MPN patients.
Healthtree contact John Mascarenhas, MD

John Mascarenhas, MD

John Mascarenhas, MD, is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Mascarenhas is the Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, directs the Adult Leukemia Program, and is a member of The Tisch Cancer Institute. His clinical and research focus centers around myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). Throughout his illustrative career, Dr. Mascarenhas has published over 275 papers, is the principal investigator for the National Cancer Institute sponsored Myeloproliferative Disease Research Consortium, and has served as principal investigator or study chair on numerous clinical trials geared toward innovative treatment approaches for MPNs and AML. Dr. Mascarenhas is widely recognized for his work in MPNs and is often invited to speak at conferences for his expertise in the field.
Healthtree contact Raajit Ramal, MD, PhD

Raajit Ramal, MD, PhD

Raajit Rampal, MD, PhD, is a Hematological Oncologist at the Memorial Sloan Kettering Cancer Canter, New York, KY, specializing in myeloproliferative neoplasms (MPNs) and leukemia. Dr. Rampal is a dedicated and active researcher focusing on developing new and innovative approaches to treating MPNs and leukemia. He also works to develop and run novel clinical trials with molecularly targeted agents for patients with MPNS and leukemia.